Soligenix, Inc. $SNGX

What the company doesAI summary of filing

Soligenix is a late-stage biopharmaceutical company developing products for rare diseases with unmet medical needs across two segments: Specialized BioTherapeutics and Public Health Solutions. In Specialized BioTherapeutics, the company is developing HyBryte (synthetic hypericin), a topical photodynamic therapy for cutaneous T-cell lymphoma that completed a Phase 3 trial and began a confirmatory Phase 3 study in December 2024, as well as expanding synthetic hypericin into psoriasis (SGX302) and developing dusquetide, an Innate Defense Regulator for aphthous ulcers in Behçet's Disease (SGX945) and oral mucositis in head and neck cancer (SGX942). In Public Health Solutions, the company is developing vaccine candidates including RiVax for ricin toxin, programs targeting filoviruses like Ebola and Marburg, and a COVID-19 vaccine candidate, supported by government funding. The company is clinical-stage with no approved products and generates revenue through government grants and contracts. [10-K 2026-03-31]

Segments: Specialized BioTherapeutics - HyBryte (synthetic hypericin/photodynamic therapy), Specialized BioTherapeutics - SGX302 (synthetic hypericin for psoriasis), Specialized BioTherapeutics - Dusquetide (Innate Defense Regulator technology), Public Health Solutions - Vaccines and therapeutic candidates